You are here

Etanercept (Enbrel) Biosimilar Meets Goal in Late-Stage Study

Product shows clinical equivalency in RA patients

CHS-0214 (Coherus BioSciences/Baxalta Inc.), a proposed biosimilar of etanercept (Enbrel, Amgen), has met its primary endpoint in a phase 3, double-blind, randomized, controlled clinical trial. This ongoing, 52-week study is evaluating the efficacy and safety of CHS-0214 compared with etanercept in patients with moderate-to-severe rheumatoid arthritis (RA) that has been inadequately controlled with methotrexate alone.

The study’s primary efficacy endpoint was the proportion of subjects achieving a 20% improvement according to the American College of Rheumatology criteria (ACR20) at week 24. This endpoint was within the prespecified margins for demonstrating the equivalence of CHS-0214 compared with etanercept. There were no clinically meaningful differences in the safety and immunogenicity profiles of the two products.

CHS-0214 was previously evaluated in two single-dose, crossover pharmacokinetic (PK)/bioequivalence studies in healthy volunteers. In both trials, CHS-0214 demonstrated a PK profile similar to that of etanercept based on prespecified PK criteria. The safety profiles of CHS-0214 and etanercept were similar in these studies.

CHS-0214 was also evaluated in a confirmatory, double-blind, randomized, controlled, phase 3 study in patients with moderate-to-severe chronic plaque psoriasis.  At week 12, the co-primary endpoints –– the mean percent change in the Psoriasis Area Severity Index (PASI) from baseline and the proportion of subjects achieving 75% improvement in the PASI from baseline  —were within the prespecified margins for demonstrating the equivalence of CHS-0214 compared with etanercept. There were no clinically meaningful differences in the safety profiles of the two products.

Source: Baxalta; January 11, 2016.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function